IK-13

General Information


DRACP ID  DRACP01060

Peptide Name   IK-13

Sequence  CIIKKIIKKIIKK

Sequence Length  13

UniProt ID  Not available

PubChem CID  Not available

Origin  AMP

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HCT 116 Colon carcinoma Carcinoma IC50=29±6 µM MTT assay 72h 1
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=47±5 µM MTT assay 72h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HDF: IC50>100 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01060

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C75H145N19O14S

Absent amino acids  ADEFGHLMNPQRSTVWY

Common amino acids  IK

Mass  178340

Pl  11.1

Basic residues  6

Acidic residues  0

Hydrophobic residues  6

Net charge  6

Boman Index  -250

Hydrophobicity  46.92

Aliphatic Index  180

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 34509120

Title  Rationally designed short cationic α-helical peptides with selective anticancer activity

Doi 10.1016/j.jcis.2021.08.200

Year  2022

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.